Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News & nice update
http://www.baystreet.ca/quotedata/news-article.aspx
Propanc Secures Financing to Complete Preclinical Animal Studies and Progress Company towards Human Trials; Updates on Progress and Plans
MELBOURNE, AUSTRALIA / ACCESSWIRE / October 1, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced a summary of current activities and recent achievements which will see the Company ready to complete several important milestones in the coming months.
Propanc Raises First $1.2 Million of Potential $4 Million Deal:
Recently, the Company issued a note with a principal amount of $1.2 million to an institutional investor as a bridge financing to a larger, subsequent financing that may have the potential to provide the Company with up to $4.0 million. If both parties proceed, the aggregate deal size will be sufficient to cover current and future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP.
The Company provided further information regarding this financing in a Form 8-K filed with the SEC on September 29, 2015.
Numerous Preclinical Activities Underway for The Company's Lead Product, PRP:
Animal efficacy studies in several tumor cell lines are underway for PRP with the Company's research partner, vivoPharm, in Hershey, PA. The studies are investigating the optimization of the PRP treatment, which are expected to even further improve PRP's anti-tumor effects compared to the previous pilot studies. The human xenograft orthotopic models (human derived tumors transplanted into immunocompromised mice) will be used to support upcoming regulatory agency meetings and licensing discussions.
Additionally, pharmacokinetic studies are underway in order to generate important information regarding how the two proenzymes in the PRP formulation are metabolized throughout the body. The data generated will provide important information regarding dosing for each of the two proenzymes and therefore optimizing the treatment regimen for PRP in future human studies.
One additional animal efficacy study conducted at vivoPharm has incorporated a mouse tumor transplanted in immunocompetent (immune functioning) mice. Blood and tissue samples harvested from this study are presently being prepared to be sent to Adaptive Biotechnologies in Seattle, WA, to characterize the immune response when compared to untreated and PRP treated mice.
Important Scientific Discoveries Resulting in Additional Patent Applications:
Whilst undergoing cell culture studies investigating the effects and underlying mechanisms of PRP treatment at the University of Ja?n in Spain, it was recently reported that important scientific observations were made which has been sent to the Company's patent attorneys for evaluation. Since then, additional experiments have been conducted confirming the initial results.
Coincidentally, results from recent animal studies conducted at vivoPharm in Hershey, PA, have also been sent to the Company's patent attorneys for evaluation.
The Company's lawyers are preparing provisional patent applications and are presently waiting on further results from both research partners in order to maximize the strength of each application.
The Company reaffirms its commitment to announcing findings from these recent studies to shareholders at the earliest opportunity, once the patent applications are filed. Management is excited about these results which helps to further establish the Company's intellectual property portfolio, as a global leader in the field, which they believe has significant implications regarding the commercial potential of PRP as a long term therapy for the treatment and prevention of metastatic cancer from solid tumors.
Preparation for Regulatory Agency Meetings and Initiation of Partnering discussions:
Preparation is underway for planned regulatory agency meetings early next year, where Propanc management is expected to meet with the Federal Institute for Drugs and Medical Devices in Germany (BfArM), European Medicines Agency (EMA) and US Food and Drug Administration (FDA). The scientific advice meetings will be an opportunity to discuss key activities planned for the future development of PRP, including animal safety/ toxicology studies and the proposed clinical pathway for human studies in Phase I and II.
Orphan Drug Designation:
Further, as a result of completing the recent cell culture and animal studies with its research partners, the Company has selected pancreatic cancer as its lead indication for human studies. Given the background development history of PRP, its uniqueness as a potential treatment for pancreatic cancer, and the size of the target patient population for pancreatic cancer, management will seek Orphan Drug Designation for PRP for this indication in each jurisdiction. When a product is designated orphan drug status in a particular jurisdiction, the relevant agency will assist with advising the Company on its development activities, reduce the costs of various regulatory agency submissions and provide market exclusivity for a period anywhere between 7 to 10 years.
Once the scientific advice meetings with regulatory agencies are completed, the Company will engage potential licensing partners to determine their interest in partnering with Propanc as it enters human trials next year.
Evaluation of Overseas R&D tax Schemes and Government Grants:
The Company over a number of years continues to receive an R&D tax refund from the Australian Government for its research and development activities. Since broadening its level of R&D activities all over the world, the Company has decided to undertake a strategic evaluation of countries around the world which fund R&D and where it could potentially qualify for government grants. Management has decided to focus its efforts into researching grants in the US and EU, which could not only reimburse R&D activities undertaken, but could also provide a potential source of financing for future R&D activities for its lead products and research programs.
Plans for Listing on a National Exchange:
The Company's management team continues to work closely with its advisors and has carefully considered all financing deals presented to ensure any investor is supportive towards the Company's ambitions for up listing onto a national exchange. If the current institutional investor decides not to proceed with the subsequent financing, management is confident the Company remains an attractive opportunity to investors willing support its plans to up list sometime next year.
"We are extremely pleased with the progress made with our recent financing and R&D activities," said James Nathanielsz, Propanc's Chief Executive Officer, "The important, incremental, but necessary steps taken this year, has enabled us to grow in confidence that we are on the right pathway to achieve long term commercial success."
Propanc aims to fast track the development of proenzyme related oncology products into clinical trials for colorectal and pancreatic tumors, initially. According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
About Propanc:
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc's products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, Propanc intend to develop their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Contact:
Regal Consulting
Tel: 702 – 575 – 9157
SOURCE: Propanc Health Group Corporation
Source: Accesswire (October 1, 2015 - 8:01 AM EDT)
News by QuoteMedia
www.quotemedia.com
HTE is up 35% today on much higher than average volume on the Warsaw Exchange - I can not find any news but
One can only deduce something good is cooking in Poland
http://www.gpwinfostrefa.pl/GPWIS2/pl/emitents/quotations/TERRA,PLTERRA00016
$65K BID @ .65! Nice close haha PUSH!
It is the Cadillac @EquityFeed ...has all those features & much more
If you trade many different stocks as I do, and particularly for pennies it is must have imo
Also heightens the experience on $TPIV today watching L2 ;) some LARGE ask slaps .. saw one an hour ago in excess of $12K @.615 .. am in and out of my office ..several more today in the $5K range..
Love the way we are trading today nothing parabolic, nice steady rise dips all bought and holding up with most day traders exiting and nearly done if not all done by now
I think we will see a new HOD close.. sure behaving like it wants to on L2
Those on a 15 min delay are already out of time for anything under .65 lol
Disclaimer to the board: I am not here peddling Equity Feed under the referral program they have, I sent Blu a link directly to their site .. I truly don't know how I'd live without it and my endorsement of their software comes free of charge to everyone
$TPIV Conference Call tomorrow 11AM EST
http://www.prnewswire.com/news-releases/tapimmune-to-provide-update-on-and-confirmation-of-phase-ii-clinic-trial-initiation-300140867.html
Solid $ here + low float = KaKaBOOM "I'm a Believer"
Nice execution on this HUGe & well timed PR leading in to the CC tomorrow indeed exciting times have arrived
Moving on UP! ... UP Where We BELONG!
TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer
Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization
JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ --
TapImmune, Inc. (OTCMKTS: TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.
Award recipients are Keith L. Knutson. Ph.D., professor of Immunology at the Mayo Clinic Center for Immunology and Immune Therapies, and Edith A. Perez, M.D., deputy director at large for Mayo Clinic Cancer Center and the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine, both at Mayo Clinic's Florida campus in Jacksonville.
TapImmune, a clinical stage cancer immunotherapy company, has the commercial rights for this vaccine, which has the potential to treat ovarian, breast, endometrial and non-small cell lung cancer. The Company has been working closely with Dr. Knutson on the clinical development of HER2/neu and Folate receptor alpha vaccines. TapImmune will work closely with Mayo Clinic on this clinical trial by providing clinical and manufacturing expertise as well as providing GMP vaccine formulations. These vaccine formulations are being developed for multiple Phase II clinical programs in triple negative breast and ovarian cancer in combination with other immunotherapeutics.
TapImmune recently announced positive Phase 1 clinical data from the Folate Receptor Alpha vaccine trial in triple negative breast and ovarian cancer. This trial demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response in 19 out of 20 patients. Data from the Phase 1 trials were submitted and published in abstract form http://meetinglibrary.asco.org/content/148110-156.
The Company plans to utilize funds from its recently restructured financing to start Proof of Concept Phase 2 clinical studies in triple negative breast and ovarian cancer patients beginning the second half of 2015. The design of these studies will complement that of the clinical trial to be conducted at Mayo Clinic.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated "We congratulate our collaborators on this outstanding achievement. This award from the Department of Defense will fully fund a large Phase II trial on the folate receptor alpha vaccine, greatly expanding clinical programs on the Folate receptor alpha vaccine and is synergistic with our own clinical pathway. In addition, our ability to contribute GMP manufactured vaccines should greatly facilitate this program. Department of Defense financing is part of its long standing commitment to breast cancer research and the combination of this grant together with our own independent financing of clinical programs provides a significant boost to developing this extremely promising approach to provide new therapeutic options for the treatment of triple negative breast cancer."
Mayo Clinic and Dr. Knutson have a financial interest in TapImmune, sponsor of the clinical trial.http://www.prnewswire.com/news-releases/tapimmune-vaccine-to-be-studied-in-a-133-million-us-department-of-defense-grant-to-mayo-clinic-for-phase-ii-clinical-trial-in-triple-negative-breast-cancer-527664171.html
I agree and added today this is a clear signal there is business at hand and further communications shortly ..let the uptrend begin & sustain!! Knock our socks off $HPTG!
$TPIV We have news - the countdown is on for Phase I update and entry into Phase II Sept 9th @ the Rodman & Renshaw Global Investment Conference
http://www.prnewswire.com/news-releases/tapimmune-inc-to-present-at-17th-annual-rodman--renshaw-healthcare-conference-300136669.html
$PPCH Wow My market order entered P/M took forever to fill ..MM's had some 'short' business first I guess ..added to my stash - long
$PPCH Patent Approval News
https://www.accesswire.com/431639/Propanc-Receives-Patent-Approval-in-Key-Jurisdiction
Propanc Receives Patent Approval in Key Jurisdiction
MELBOURNE, AUSTRALIA / ACCESSWIRE / August 31, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced that the Company's Australian patent application covering its lead product PRP was accepted recently by the Australian Patent Office.
The Australian patent application describes a pharmaceutical composition for treating cancer comprising the proenzymes trypsinogen and/or chymotrypsinogen, as well as several other active agents disclosed in the patent.
Importantly, claims directed to compositions, as well as method of treatment claims, were accepted by the Australian Patent Office. This is considered a great result as composition claims are often difficult to patent and are considered more valuable commercially.
Propanc's lead patent application is now accepted or granted in Australia, New Zealand and South Africa, and under examination in key global regions such as the United States and European Union. The Company expects the recent acceptance in Australia to support ongoing applications in other territories under examination.
Propanc aims to fast track the development of proenzyme related oncology products into clinical trials for colorectal and pancreatic tumors initially. According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015.
"The Propanc management team are very pleased with our recent patent acceptance in Australia," said James Nathanielsz, Propanc's Chief Executive Officer. "The combined market for pancreatic and colorectal cancers is around ten billion dollars and we believe PRP could make a real difference for patients suffering from these diseases. Establishing a first class intellectual property portfolio is the cornerstone for supporting this vision."
About Propanc:
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc's products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, Propanc intend to development their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Party's just starting..any accumulation under .10 will look cheap in the very near future
$PPCH
Bargains presented EVERYWHERE today!-purely emotional exits=where the real money is made-I stole a few @.32
$LEOM long
Stop sign gone - SEC Reporting - Current
Wasn't expecting much from the Q's the important thing is they are filed and will allow the recovery plan to finally move forward ..
One small step for minions .. One giant leap for $MLHC
http://www.otcmarkets.com/stock/MLHC/quote
Q filings caught up now it's go time should see a few upticks on this merit alone notwithstanding news on the close of the merger with Bluestar and any other further developments on the road to recovery
https://www.sec.gov/cgi-bin/browse-edgar?company=m+line+holdings&owner=exclude&action=getcompany
$MLHC
Nice news just hit the wires ..great to see we are focused on cutting edge modern technology as another cog in the wheel to leading the industry
Leo Motors Launches "Connected" Electric Vehicle and Boat Project
SEOUL, SOUTH KOREA / ACCESSWIRE / August 18, 2015 / Leo Motors Inc. (OTCQB: LEOM) ("LEO") entered into Memorandum of Understanding with LG Uplus Corporation (LGU+) for development of hardware and software protocols for connected Electric Vehicles (EV) and Electric Boats (EB) based on the Internet of Things (IoT) technology.The collaboration between LEO and LG will establish a telecommunication infrastructure for electric vehicles and boats, thereafter developing a total service solution that integrates control and interactive devices for electric vehicles, boats, and their respective charger utilities.
They will also create new business service networks for electric vehicles and boats using Internet of Things (IoT) platforms.
Dr. Kang, CEO of Leo said, "Using the IoT platform, our development will include battery charging or replacement alert services and nearest juice outlet information services based on vehicle range monitoring. We will also provide cloud based electric power management and condition of electric power train monitoring services as well as EV fleet management services, roadside emergency battery charging or replacement services, and payment and self-certification services on the chargers."
A subsidiary of the LG group, LGU+ is recognized as a leading telecommunication company, and is a pioneer of Long Term Evolution (LTE) telecommunication technology. In the years 2011 through 2013 LGU+ developed and operated EV charging stations in Jeju Island in Korea as an integral part of a Smart Grid infrastructure project.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.
About Leo Motors, Inc.
Leo Motors, Inc., through its subsidiary Leo Motors, Co. Ltd., is engaged in the research and development (R&D) of multiple products, prototypes and conceptualizations based on electric power generation, drive train and storage technologies. Leo Motors, Co. Ltd. operates through four unincorporated divisions: new product research & development (R&D), post R&D development such as product testing; production; and sales. The Company's products include, E-Box electric energy storage system for solar and wind power generation devices; EV components that integrate electric batteries with electric motors such as EV Controllers that use a mini-computer to control torque drive.
For more information please call
Princeton Research, Inc
Mike King 702 650 3000
SOURCE: Leo Motors
https://www.accesswire.com/431390/Leo-Motors-Launches-Connected-Electric-Vehicle-and-Boat-Project
Added some here today on the PR .. nice steady here I think a little rally this afternoon is in order .. hoping not too fast to be honest I am comfortable in my recliner and off the edge of my seat lol Easy does it would be nice climbing slowly from here will be a great set up for next chapter coming soon
Very thin up to new highs & zero dilutors ...
I believe there are more shares long holding this than this board seems to perceive ..the march thru .10 will be faster w/ far less resistance this time
FWIW
Chaikin Money Flow went green again early August
http://stockcharts.com/h-sc/ui?s=PPCH&p=D&b=5&g=0&id=p38435427526
Welcome aboard & Congrats! Nice to have you here I think you made a wise decision at a great time
.50 has been a bit of a tough nut to crack but today more than ever hitting the tape @ .50 and as always of late, significant sized blocks ...won't be long till we break resistance here & carry on up!
I know what you mean by watching & waiting ... I too have felt this is a high caliber & quality stock especially for an OTC for more than 2 years now
Flies under the radar with retail atm but I kind of like that here no P&D's forcing one's hand in and out.
I so wish I could have all the shares I flipped back now when it was in the .04 - .09 channel lol
I have no intention of selling this one anytime soon only adding they are on a great path in emerging disruptive industry and the eastern half of the world is in fact creating much higher demand for EV's than we are in NA
Not to mention the government support, and contracts this is a no brainer
Well positioned WINNER imo
Lovn' my $LEOM
One World Holdings CEO Issues Shareholder Update Letter
HOUSTON, TX / ACCESSWIRE / August 11, 2015 / The One World Doll Project, a subsidiary of One World Holdings, Inc. (OTCQB: OWOO), announced today that its CEO, Corinda Joanne Melton has issued a shareholder update letter.
The letter is currently available on the company website at http://oneworlddolls.com/815ceoletter and will also be filed in an 8k with the SEC later today. The full context of the letter is as follows:
Dear One World Stockholder,
As we enter into our final push the upcoming national roll out of The Prettie Girls! Tween Scene dolls in over 2,900 Walmart stores, I wanted to take a few moments to update everyone on the progress the company has made since my last letter. To begin, it is my pleasure to inform you that as of August 10 the company has received major retail purchase orders totaling over $855,000 and this has been achieved prior to our busy Holiday sales season! The Prettie Girls! brand is growing and we are extremely enthusiastic about the strides we have made thus far in 2015.
The Prettie Girls! Dolls have received new purchase orders from Walmart.com.
On our most recent conference call our Founder announced that we were expecting purchase orders from Walmart.com for the Prettie Girls! Tween Scene line and I am pleased to inform you that we now have those purchase orders in hand. As anticipated, the Walmart.com buyers opted to carry the new Tween Scene dolls and also the entire line of six Tween Scene fashion accessories as well. We are currently completing production on these new orders and will soon begin shipping to U.S. distribution centers. We expect the dolls and accessories to appear on Walmart.com by mid-October.
The Prettie Girls! dolls have some baby siblings on the way.
Last year, we received an inquiry from another of America's largest retailers about supplying a line of toddler dolls and we are pleased to announce the debut of The Prettie Girls! Dream Babies at the Toy Industry Association Fall Toy Preview in Dallas, Texas this October. These dolls will feature an 18 inch, plush body sculpted by world renowned doll designer, Robert Tonner and exclusive toddler fashions designed by Prettie Girls! creator, Stacey McBride-Irby. Our plan is to roll out The Prettie Girls! Dream Babies for the Spring 2016 retail season. We will keep you updated as development on this line progresses.
Let's bring some clarity to our share structure.
At this time we are very happy with the results of our efforts to improve the company share structure by focusing on the elimination / consolidation of convertible debt held by what we classify as aggressive sellers. Over the past year, we have successfully eliminated or consolidated a large portion of this convertible debt and at this time the company has no plans to increase our authorized shares above the current 500 million.
Summary
We truly hope that as the future unfolds, you will continue to be on this journey with us, and we ask you and thank you for your continued support of The One World Doll Project and The Prettie Girls! product line.
Sincerely,
Corinda Joanne Melton
CEO
One World Holdings, Inc.
About The One World Doll Project
Established in 2010 by Trent T. Daniel and Stacey McBride-Irby, The One World Doll Project is committed to changing the retail landscape of the doll industry. The Prettie Girls!(TM), are a collection of fashion play dolls diverse in culture, interests, and style. McBride-Irby, former Mattel(R) designer most notably known as creator of the So In Style(R) dolls (the first African-American dolls by Mattel), designed the Prettie Girls! as unique works of art for a growing market yearning for something new to experience. The Prettie Girls! capture the essence of positive values and attributes that every little girl can embrace."Prettie" stands for P(ositive) R(espectful) E(nthusiastic) T(ruthful) T(alented) I(nspiring) E(xcellent). Styled for play, yet filled with soul, The Prettie Girls! set new, higher, values-based standards for beauty-positive goals that reach across the globe and up for the stars!
More information about Stacey McBride-Irby, Trent T. Daniel, and The One World Doll Project, can be found at www.oneworlddolls.com.
SOURCE: One World Holdings, Inc.
https://www.accesswire.com/431206/One-World-Holdings-CEO-Issues-Shareholder-Update-Letter
Nice chart assessment!
Add to that a whole lot of pent up demand for a quality, fundamentally strong strong stock, waiting on the sidelines that will pounce back in here on this confirmed reversal, and this chart will be even juicier after Monday heading in to the upper channel of the bollies
Pretty safe to say this is as safe as entry/adding will get it is going back up from here tiny tightly held float will make moves fast & furious when more buying pressure arrives.
The CMF remained respectable through that short term downturn and has gone green again on the daily, remains very green on the weekly and the Accum/Dist has marked a steep and complete reversal on the weekly.
...notable stronger accumulation started again late July
..clearly reversal time is here with many eyes who won't let it get away
M/C is silly at this juncture very attractive buy here ..
Daily w/ Accum/Dist & CMF
Weekly w/ Accum/Dist & CMF
Here's to a much deserved rocking & rally week! GLTA
$TPIV
There are so many exciting developments and moving parts to this enterprise!
To answer your request, this is an extremely busy time of year for my business but when I do have some spare time I will see what else I can dig up to add to the ibox .. the patent links from their website I can not decipher as they are written in Korean and google can't translate for me so I am at a bit of a loss as to what the patents are and actually protect as part of our IP .. certainly an impressive effort by the company to develop and take the necessary steps to ensure long term success.
Ah yes the Zinc Air Fuel Cell that dramatically extends range and reduces cost
There are several presentations/news stories on YouTube, most in Korean, but nevertheless easy to see it is a significant development with notable government officials and scientists/engineers in attendance at a Leo Motors seminar in the second video
Very nice week here! ..and indeed seems ready for the next leg up beyond .50's as we went from the bottom bollie to the top to finish the week...very bullish and nice volume on that huge news
For quite some time now most of the buying is in VERY large blocks and not likely retail but rather institutional building positions.
That's when I know I have found a gem for a long term hold ..follow that BIG money!
M/C actually still very undervalued imo @ $70M .. in the short term I don't think it will be much longer before there is a $ sign in front of our pps
Leo Motors Launches Major Joint Venture In China
SEOUL, SOUTH KOREA / ACCESSWIRE / August 6, 2015 / Leo Motors Inc. (OTCQB: LEOM) ("LEO") has signed a joint venture agreement with Fushun Jinyuan Technology Machinery Manufacturing Co., Ltd. ("JTY" or "Jinyuan") to set up a Joint Venture Company ("JVC") in Fushun City in Liaoning Province of China to develop, manufacture and sell electric cars for Chinese and international markets. The initial investment of the JVC is 411,600,000 Chinese Yuan or $ 66 million U.S. dollars.
LEO's proprietary technologies will be utilized in electric cars manufactured by the JVC, which will be sold to both government offices and private companies in three Northeastern Provinces of China (Liaoning, Jilin and Heilongjiang) encompassing eastern Inner Mongolia, beginning in 2016.
China has mandated that by 2016 thirty percent (30%) of all new government vehicle purchases are to be electric powered in order to fight pollution and cut energy use. The mandate is facilitated by an exemption from sales tax.
In spite of the central government's mandate, there are very few electric vehicles in three Northeastern Provinces because of the extremely cold winters, at times dropping below -22 degrees F. In such cold temperatures traditional batteries do not function, making electric vehicles useless.
LEO has solved the cold region problem with its recently invented electric vehicle battery power pack using Nano Carbon Technology ("CNT") which works and supplies full power in low temperatures (under -22 degrees F) without any capacity or power loss.
LEO was invited to participate in this new business venture by the city government of Fushun. Fushun city officers introduced Leo to Jinyuan, the largest private company in Fushun City. Because of their role in facilitating the new venture all important Fushun City officials including the mayor, deputy mayor, and major directors and managers attended the agreement signing ceremony.
In the interview with local press at the signing ceremony, Mr. Si Guicheng, the chairman of Jinyuan, stated, "The government projects the demand for electric vehicles from the three Northeastern Provinces exceed one million units including electric buses, garbage trucks, city cleaning trucks, fire engines, and official or public business cars. The JVC is expected to supply 30,000 electric vehicles to the government within the first year of manufacturing as we monopolize the regional electric vehicle market based on LEO's CNT battery power pack technology. Sales are expected to exceed 10 billion Chinese Yuan (approx. $1.67 billion USD) per year."
(Source of the photo: http://www.fs024.com/3g/wapNews.aspx?dataID=38154)
Dr. Shi Chul (Robert) Kang, CEO of Leo stated, "LEO's sales are expected to reach 4 billion Yuan (approx. $643 million USD) annually based on our priority rights to supply power trains including motors, controllers and battery power packs for the electric vehicles manufactured by the JVC." He also said, "From the foundation of our experience in the Northeast China, we will aggressively expand our business into the electric vehicle markets of all extreme cold regions in the world, including Russia, Alaska, Norway, Finland, etc. Our CNT battery power pack is the ultimate marketing edge for electric vehicles in extremely cold regions in the world."
It is important to note that LEO will receive ten percent (10%) of the JVC gross profit for ten years as a technology transfer fee.
Leo has the exclusive right to market and sell electric vehicles manufactured by the JVT outside China. Dr. Kang added, "We have recently invented additional major new technologies which make electric vehicles more sustainable including an electromagnetic prevention circuit, a handy and low cost battery swap system, a circuit breakage prevention system, cartridge batteries, and 'cloud based' computer-connected electric power trains. These technologies are essential to increase electric vehicles' safety and sustainability in all of the climates and will change the world's concept of electric vehicles versatility and reliability."
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.
About Leo Motors, Inc.
Leo Motors, Inc., through its subsidiary Leo Motors, Co. Ltd., is engaged in the research and development (R&D) of multiple products, prototypes and conceptualizations based on electric power generation, drive train and storage technologies. Leo Motors, Co. Ltd. operates through four unincorporated divisions: new product research & development (R&D), post R&D development such as product testing; production; and sales. The Company's products include, E-Box electric energy storage system for solar and wind power generation devices; EV components that integrate electric batteries with electric motors such as EV Controllers that use a mini-computer to control torque drive.
Contact:
For more information please call
Princeton Research, Inc
Mike King 702 650 3000
SOURCE: Leo Motors
https://www.accesswire.com/430994/Leo-Motors-Launches-Major-Joint-Venture-In-China
Other then the minor dip the pps took (typical penny players would view this as bad news) I believe this company will be using this increase responsibly to grow the enterprise.
Still a very low float & A/S here especially for the large ticket revenues coming to fruition this year... this stock will handle it just fine with the news pipeline, buying pressure will continue for many moons.
$LEOM still in it's relative infancy, is the Tesla of Asia & more!!
My next post is a tidbit for you to enjoy your coffee with this morning I know I will ;)
$LEOM
I wish it was still here.. I found it both extremely amusing and so true on point!!
I wanted to show it to my wife just now lol is why we're here ..dang
Keep up the great posting to both of you ;)
$TPIV
TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications
Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trial
SEATTLE, July 27, 2015 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the laboratory of Keith Knutson, Ph.D., at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer.
TapImmune recently announced positive Phase 1 clinical data from the Folate Receptor Alpha trial in triple negative breast and ovarian cancer. The trial demonstrated the experimental therapy was safe, well-tolerated, provided a robust immune response, therefore, TapImmune plans to initiate a Phase II clinical trial in triple negative breast cancer during the second half of 2015. Under the license agreement the IND covering the clinical trial will be transferred to TapImmune.
Dr. Glynn Wilson TapImmune's CEO stated "This agreement confirms our intent to further develop and commercialize our novel folate receptor alpha vaccine technology. Folate receptor alpha is an excellent therapeutic target in ovarian, triple negative breast and non-small cell lung cancer. Our immediate plans are to conduct Phase II studies in triple negative breast and ovarian cancer. We are excited by the recent Phase I data and our future clinical programs will be aimed at developing this leading vaccine candidate as a stand-alone therapy or in combination with other immunotherapies."
Mayo Clinic has a financial interest in the technology described in this press release. Revenue Mayo receives is used to support its not-for-profit mission in patient care, education and research.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.
Glynn Wilson, Ph.D.
Chairman & CEO
(866)-359-7541
PCG Advisory
Kirin M. Smith
Chief Operating Officer
(646)-863-6519
www.pcgadvisory.com
Sean Leous
Chief Communications Officer
(646) 863-8998
www.pcgadvisory.com
J. Streicher Capital, LLC
Robert Giordano
917-327-3938
SOURCE TapImmune, Inc.
http://www.tapimmune.comhttp://www.prnewswire.com/news-releases/tapimmune-announces-finalization-of-license-agreement-with-mayo-clinic-to-commercialize-a-folate-receptor-alpha-vaccine-for-multiple-cancer-indications-300118903.html
Was not news from Propanc yet, but rather OTC Markets Disclosure & News Service http://www.otcmarkets.com/stock/PPCH/news/OTC-Markets-Group-Welcomes-Newly-Verified-OTCQB-Companies-%E2%80%93-July-20?id=109981&b=y
Good sign sellers are exhausted at this level .. sure was an abrupt cease fire .. held up nicely yesterday bouncing off the 50 and with standoff here today I'd say we rise from here
Dog days of summer ..I think tomorrow morning I'll mow the lawn and then watch the grass grow instead
Expanding horizons some more w/MOU with the Korea Institute for Military Affairs, a subsidiary of the Ministry of National Defense of Korea!
https://www.accesswire.com/430566/Leo-Motors-and-LGM-Expands-into-Military-Business
Leo Motors and LGM Expands into Military Business
SEOUL, SOUTH KOREA / ACCESSWIRE / July 14, 2015 / Leo Motors Inc. (OTCQB: LEOM)'s wholly owned subsidiary, LGM, entered into Memorandum of Understanding with the Korea Institute for Military Affairs (KIMA), a subsidiary of Ministry of National Defense of Korea for further collaborative development of two projects: an interactive "Connected Life Jacket" and interactive, cloud connected, military electric smart boats.
LGM developed the Connected Life Jacket. It has mobile connectivity, and features an automatic heating mechanism. Upon entering the water, whether by accident or as a result of combat, the Connected Life Jacket's water sensors automatically activate a heating mechanism to defend against hypothermia associated with cold water. The Connected Life Jacket also sends an SOS signal to an emergency center. While extending survival time in freezing, the Jacket also provides an exact GPS location to rescue teams who are further assisted by a low light sensor activated LED spot lamp night rescues.
LGM has also developed an electric "smart" boat with tidal water capabilities. Its smart features include a management system assisted by the cloud super computers. Being electric, the boat is also eco-friendly as it does not emit pollutant waste. Additionally, as a military vessel it has the advantage of not making engine noise where stealth is a desirable factor.
According to Dr. Kang, chairman of Leo Motors, Inc., "LGM's smart electric boat called the 'RoBoat' can navigate in the ocean like a drone and perform difficult unmanned jobs including rescuing survivors in troubled water and such things as submarine detection in otherwise risky conditions."
By entering the MOU, KIMA and LGM will collaborate in the further development of the most appropriate military defense capabilities for both the LGM Life Jacket and the LGM electric boats.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.
For more information please call
Princeton Research, Inc
Mike King
702 650 3000
SOURCE: Leo Motors
Leo Motors Inc.
Industry:
Automotive
that and vacation mode drizzle .. imo near the end of the day no one will want to be with out TPIV heading in to next week there is a very good chance we finish green
Have a great long week end to the best board on the Hub!
Nothing wrong with a holding pattern - so much more of the float is on lock down from the past several weeks of the V's & CANT accumulating and the large sized buys we still see every day keeping it EXTREMELY thin UP
9's will be air now on a run .. next wall is at a $1 LOL
Look forward to whatever good news comes first!
$PPCH
Wish I could add today I am literally "Tapped" after adding yesterday @ .83 & .88 lol...unless I sell something else ...and I might
Didn't think it was quite this volatile here
Happy to accumulate though I am beyond my initial goal thanks to the drop and in the long run better off holding all ..this is a no brainer ..fantastic place to send some $oldier$ for summer they will conquer and bring back an army
$TPIV FTW GLTA
I am certain they will make mention of this development in a PR soon .. the filing states the intent .. a formality and protocol for SEC reporting entities
It was a quiet after hours filing .. not a PR
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10777946
Congrats I think you've made a stellar choice .. I was extremely fortunate to have 'lasers" show me the way here and started my accumulation nearly a month ago ... have not sold a share
The key to the BIG money with a winner is withstanding the bumpy days of consolidation ... I am all over from .39 - $1.49 ..very green today with most bought under .85 but I don't flip story stocks when they are the real deal and I think this is certainly one for 2015/16 .. as does Mr. Kenneth Dart
I still have enough money for my lunch today and a beer later lol ..best of luck to you ... dust settling ..it's a great entry imo
$TPIV LONG & HOLDING
Here is another oldie but a GOODIE May 16, 2014
And the very promising results free from serious side effects during the Compassionate Use Study was before they determined that IV injection will deliver even better results
Won't happen ..
I pulled the trigger too early this morn @ 1.14 and even have a few higher I bought Wed not worried in the least am glad to add to my stash it is the share count I am focused on not so much day to day
Next week I expect 1.5 - 2 range
If by chance it dips under a dollar today (I highly doubt) there will be a feeding frenzy